Selected Publications
Rauch A, Graudieri S, Thio CL, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics, in press.
2.
Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV co-infected patients on HAART. Antiviral Therapy, in press.
Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy, 2009, in press.
Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, Sankale J-L, Ekong E, Murphy R, Kanki P, Thio CL. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in Nigeria. CID, 2009, in press. NIHMS 130120.
Hoffmann CJ, Seaberg EC, Young S, Witt MD, D’Acunto K, Phair J, Thio CL. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS, 2009, in press.
Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology, 2009 April; 49(S5): S138-S145.
Matthews GV, Seaberg EC, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Hoy J, Finlayson R, Goodman Z, Philp FH, Tang Y, Locarnini SA, Thio CL. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV co-infected individuals. AIDS, 2009 Aug 24;23(13):1707-15.
Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, Harley JB, Kilpatrick JR, Langefeld CD, Williams AH, Jegga AG, Chen J, Wills-Karp M, Arshad SH, Ewart SL, Thio CL, Flick LM, Filippi MD, Grimes HL, Drumm ML, Cutting GR, Knowles MR, Karp CL. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature, 2009 Apr; 458(7241):1039-42.
Hoffmann CJ, Charalambous J, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, Fielding KL, Thio CL. Hepatitis B Virus Infection and Response to Antiretroviral Therapy (ART) in a South African ART Program. CID, 2008 Dec; 47(11): 1479-85.
Thio CL, Astemborski J, Thomas R, Mosbruger T, Witt MD, Goedert JJ, Hoots K, Winkler C, Thomas DL, Carrington M. Interaction between RANTES promoter variant and CCR5?32 favors recovery from hepatitis B. JI, 2008 Dec; 181(11):7944-7.
An P, Thio CL, Kirk GD, Donfield S, Goedert JJ, Winkler CA. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C clearance. JID, 2008 Oct; 198(8):1159-65.
Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, Sasadeusz J, Matthews G, Dore GJ, Shaw T, Sozzi V, Yuen L, Lau G, Ayres A, Thio C, Avihingsanon A, Ruxrungtham K, Locarnin S, Revill PA. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology, 2008, Sept; 48(3):741-9.
Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS, 2008 May 11;22(8):947-55.
Domaoal RA, McMahon M, Thio CL, Bailey CM, Tirado-Rives J, Obikhod A, Detorio M, Rapp KL, Silicano RF, Schinazi RF, Anderson KS. Pre-steady state kinetic studies establish entecavir 5’-triphosphate as a substrate for HIV-1 reverse transcriptase. JBC, 2008 Feb 29;283(9):5452-9.
McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. NEJM 2007, 356(25):2614-21.
